bladder cancer
Conditions
Interventions
Control:Gemcitabine 1g diluted with 50ml normal saline
Eperimence:Gemcitabine 1g diluted with 50ml normal saline
Sponsors
The Second Hospital of Tianjin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Aged >= 18 years; 2) Histologically defined non-muscle invasive bladder urothelial carcinoma; 3) According to the 2014 edition of the guidelines for the diagnosis and treatment of urological diseases in China, the risk assessment is clearly classified as intermediate or high risk; 4) ECOG score = 5 years; 6) You can sign your informed consent form by yourself; 7) The patient has good compliance and is willing to follow up according to the program; 8) Contraceptive measures were taken from the date of screening throughout the study period until 3 months after the last perfusion treatment.
Exclusion criteria
Exclusion criteria: 1) Combined with other histological types of bladder cancer (eg, adenocarcinoma, squamous cell carcinoma, small cells, etc.); 2) Imaging examination revealed tumor metastasis in other parts of the bladder; 3) Combine other malignant tumors; 4) had an allergic reaction to gemcitabine; 5) are participating in or planning to participate in other clinical studies; 6) The urethra is narrow and cannot be inserted into the urethra; 7) Effective bladder capacity <= 50ml; 8) Previous history of intravesical infusion of gemcitabine; 9) Female pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence-free survival rate 1 year after surgery; | — |
Countries
China
Contacts
Public ContactHu Hailong
The Second Hospital of Tianjin Medical University
Outcome results
None listed